Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Efavirenz · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Ritonavir | DRUG | - |
| Efavirenz | DRUG | - |
| Saquinavir | DRUG | - |
Inclusion Criteria Patients may be eligible for this study if they: * Are HIV-positive. * Have a viral load of at least 5,000 copies/ml and a CD4 cell count of at least 75 cells/mm3. * Are at least 18. * Are able to complete the study. Exclusion Criteria Patients will not be eligible for this st...
Top 20 of 28 competitors
Efavirenz is a small molecule drug being developed by Roche Holding AG for the treatment of HIV Infections. It is currently in Phase 3 clinical development, meaning it is investigational and has not yet been approved. The drug is being studied in patients with HIV, with trials conducted in the United States, Canada, and Puerto Rico.
Efavirenz is being developed by Roche Holding AG, a company traded under the ticker RHHBY. Roche is conducting Phase 3 clinical trials to evaluate the drug for the treatment of HIV Infections. The development program includes two completed trials with a total enrollment of 186 participants.
Efavirenz is in Phase 3 clinical development for the treatment of HIV Infections. It is an investigational drug, meaning it has not been approved by regulatory authorities. Two Phase 3 trials have been completed, but the drug is not yet available as a licensed therapy.
Efavirenz has been studied in two completed Phase 3 clinical trials. The first, NCT00002447, compared two anti-HIV drug combinations in 146 participants with HIV Infections. The second, NCT00002448, compared the effects of two anti-HIV drug combinations on the immune systems of 40 HIV-infected patients. Both trials were conducted in the United States.
Efavirenz is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for the treatment of HIV Infections. While two Phase 3 trials have been completed, the drug has not received regulatory approval and remains under investigation by its developer, Roche Holding AG.